Boehringer Ingelheim is a research-driven company operating worldwide under two divisions: Human Pharmaceuticals and Animal Healthcare. In oncology, Boehringer Ingelheim is mainly focused on three areas: angiogenesis inhibition, EGFR inhibition and cell cycle kinase inhibition.
C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim GmbH, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany.
- In Jan 2021, Boehringer signed agreement with Enara Bio (formerly Ervaxx) to discover and validate novel Dark Antigens in up to three tumor type Vaccines in the lung and gastrointestinal cancer space leveraging Enara Bio’s proprietary Dark Antigen Platform Technology (EDAPT™. Under the terms, Boehringer has the option to license Dark Antigens and will also be responsible for all non-clinical and clinical development, as well as commercialization of associated cancer immunotherapies. Enara is also eligible to receive more than EUR 876 Mn in clinical, regulatory and commercial milestones, in addition to royalties on future product sales.
- In July 2020, Numab Therapeutics and Boehringer Ingelheim enter into collaboration to develop multi-specific antibody therapeutics targeting difficult-to-treat lung and gastrointestinal (GI) cancers and retinal diseases utilizing Numab’s multi-specific antibody platform.
- In Feb 2020, Boehringer Ingelheim collaborate with Trutino Biosciences to access the company’s OnDemand-Cytokine™ (ODC)platform to develop new cancer immunology compounds. The partners aim to develop safer, more tolerable and more effective cytokine therapies for single agent and novel combinations with Boehringer Ingelheim’s innovative cancer vaccine, oncolytic virus, T cell engager and myeloid-targeting therapies.
- In Sep 2019, Lupin Ltd. and Boehringer Ingelheim announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. Under the terms, Lupin received an upfront payment of $20 Mn with additional payments of aprox. $700 Mn in successful achievement of agreed clinical, regulatory and commercial milestones. Lupin is also eligible to receive double-digit royalties on the sales of the product.
- In Sep 2019, Boehringer Ingelheim out-license Oncoheroes the intellectual property of volasertib, with exclusive rights to research, develop, sell and sublicense the compound. Volasertib is an inhibitor of Polo-like-kinase 1 (PLK1), and was developed by Boehringer for the treatment of a specific form of leukemia but clinical development activities were halted after a large Phase III study with adult patients failed to meet its primary endpoints. Further financial details remains undisclosed.
- In Dec 2018, Xynomic Pharmaceuticals, acquired worldwide license to develop, manufacture and commercialize BI 860585, a phase 2 ready mTORC1/2 inhibitor, from Boehringer Ingelheim. Xynomic plans to initiate 2 clinical trials against breast cancer. Total payments of Xynomic associated with the licensing agreement, including an upfront payment, regulatory milestone payments and potential royalties, will be up to $800 Mn.
- In Nov 2018, Boehringer and Epizyme, Inc. (Nasdaq: EPZM) signed global collaboration for the development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed epigenetic targets; within the helicase and histone acetyltransferase (HAT) families, as potential therapies for people with cancer. Under the terms, Epizyme received an upfront payment of $20 Mn and is eligible to receive more than $280 Mn in additional payments for research, development, regulatory and commercial milestones.
- In April 2018, Boehringer Ingelheim and OSE sign license agreement to jointly develop OSE-172, a first-in-class mAB antagonist of SIRPα, for advanced solid tumors. Under the terms, OSE receive a €15 Mn upfront payment from BI, and potential additional short-term milestones of up to €15 Mn upon initiation of a phase 1 clinical study. OSE stands to receive more than €1.1 billion upon reaching pre-specified development, commercialization and sales milestones, plus royalties on worldwide net sales.
- In Nov 2017, iPharma (H.K.) Ltd., acquired an exclusive worldwide license agreement with Boehringer Ingelheim, to manufacture, develop, and commercialize BI 853520, a focal adhesion kinase inhibitor (FAKi). In 2018, the global development and commercialization rights of the drug were further passed to InxMed (Shanghai) Co., Ltd.
- In Oct 2017, Xynomic Pharmaceuticals acquired exclusive global rights to develop, manufacture and commercialize BI 882370, a 2nd-generation RAF inhibitor, from Boehringer Ingelheim. Under the terms of the agreement Xynomic will pay upfront, milestone and royalty payments up to approximately $502 Mn.
- In July 2015, Boehringer acquired development and global commercialization rights, except South Korea, China and Hong Kong, of HM61713, a novel 3rd generation EGFR targeted therapy for the treatment of EGFR mutation positive lung cancer from Hanmi Pharmaceutical and paid $50 Mn as upfront and $ 680 Mn as potential milestone payments plus double-digit royalties on net sales.
- In May 2015, Eureka Therapeutics and Boehringer Ingelheim have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology.
- In Nov 2014, Boehringer acquired global commercial rights to CV9202, a mRNA vaccine in early clinical development for the treatment of lung cancer from CureVac. CureVac received EUR 35 Mn as upfront and up to EUR 430 Mn royalties and milestone.
- Boehringer Ingelheim exercised two options between 2015 and 2016 for exclusive rights to targets discovered during our research collaboration using Oxford BioTherapeutics’ proprietary OGAP® system.
- In Apr 2013, Oxford and Boehringer Ingelheim (BI) entered into an alliance focused on the discovery of novel cancer antibody targets using Oxford BioTherapeutics’ proprietary OGAP® system. BI will have the exclusive right to develop and commercialize antibody Boehringer Ingelheim is responsible for the future development and commercialization of antibody products for selected programs. Oxford will receive development and regulatory milestone payments, as well as royalties on any future product sales.
- In 2013, FORMA Therapeutics signed research alliance with Boehringer Ingelheim (BI) for the discovery of novel drug candidates against protein-protein interactions (PPI) for the treatment of cancer. Currently BI 1701963, a FORMA-discovered, BI-licensed protein-protein interaction program for patients with advanced, KRAS-mutated solid tumors is in Ph I clinical trials.
- In Mar 2011, Boehringer entered into a manufacturing agreement with MorphoSys AG for MOR208, an anti-CD19 mAb for CLL.
Page 2 of 2
